[
    [
        {
            "time": "2020-Q3",
            "original_text": "健帆生物：唐先敏合计减持0.21%公司股份 减持股份",
            "features": {
                "keywords": [
                    "健帆生物",
                    "唐先敏",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物：唐先敏合计减持0.21%公司股份 减持股份",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529.SZ)副经理唐先敏减持167.62万股 减持时间已过半 减持股份",
            "features": {
                "keywords": [
                    "健帆生物",
                    "唐先敏",
                    "减持",
                    "股份"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)副经理唐先敏减持167.62万股 减持时间已过半 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529)：三季报业绩超预期 Q3提速显著 持续引领全球血液灌流渗透率提升",
            "features": {
                "keywords": [
                    "健帆生物",
                    "三季报",
                    "业绩超预期",
                    "Q3提速",
                    "血液灌流"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：三季报业绩超预期 Q3提速显著 持续引领全球血液灌流渗透率提升",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529)：Q3利润增长加速 全年业绩可期",
            "features": {
                "keywords": [
                    "健帆生物",
                    "Q3",
                    "利润增长",
                    "全年业绩"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：Q3利润增长加速 全年业绩可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "【财报智读】健帆生物：2020年前三季度营业总收入13.15亿元，归母净利润6.27亿元",
            "features": {
                "keywords": [
                    "健帆生物",
                    "财报",
                    "营业总收入",
                    "归母净利润"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【财报智读】健帆生物：2020年前三季度营业总收入13.15亿元，归母净利润6.27亿元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529)：三季度业绩加速增长 每周1次灌流治疗写入血液净化操作规程",
            "features": {
                "keywords": [
                    "健帆生物",
                    "三季度",
                    "业绩加速",
                    "灌流治疗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：三季度业绩加速增长 每周1次灌流治疗写入血液净化操作规程",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529)：收入增速环比继续加速 肾病及肝病业务有望持续快速增长",
            "features": {
                "keywords": [
                    "健帆生物",
                    "收入增速",
                    "肾病",
                    "肝病",
                    "业务增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：收入增速环比继续加速 肾病及肝病业务有望持续快速增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物(300529)：Q3持续高增长 海外市场潜力可期",
            "features": {
                "keywords": [
                    "健帆生物",
                    "Q3",
                    "高增长",
                    "海外市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：Q3持续高增长 海外市场潜力可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物三季报点评：Q3持续高增长 海外市场潜力可期【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "三季报",
                    "Q3",
                    "高增长",
                    "海外市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物三季报点评：Q3持续高增长 海外市场潜力可期【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-Q3",
            "original_text": "健帆生物公布三季报 前三季净利增加50.13%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "三季报",
                    "净利增加"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物公布三季报 前三季净利增加50.13%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]